News Release

RIBOMIC Completes Patient Enrollment of its US Phase 2 Open-Label Extension Clinical Trial of RBM-007 for Wet Age-Related Macular Degeneration (RAMEN Study)

TOKYO, August 30, 2021 - RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TYO:4591), today announced that it has completed the patient enrollment in Phase 2 trial (RAMEN) of RBM-007 for the treatment of wet age-related macular degeneration (AMD) being conducted by its US subsidiary. The study allowed eligible subjects who have completed the ongoing phase 2 double-masked TOFU Study, irrespective of the treatment arm, to receive additional four monthly treatments of RBM-007 with no comparator. The open-label extension (OLE) study is designed to evaluate the safety and efficacy of additional intravitreal injections of RBM-007.

The company expects topline results from this trial to become available during the first quarter of 2022.

“Completion of patient recruitment in RAMEN reflects the progress the team has made and we would like to thank our clinical investigators and patients for their continued participation in the study,” said Padma Bezwada, Ph.D., CEO at RIBOMIC USA Inc. “The OLE study is expected to provide us with information regarding extended safety as well as additional insights into the efficacy of RBM-007, in particular the inhibitory effect on subretinal fibrosis, and add to the dataset of patients who have already completed the TOFU study. Following the last patient last visit, we will analyze the data and look forward to reporting the results in Q1 2022.”

About RBM-007
RBM-007 is a novel oligonucleotide-based aptamer with potent anti-FGF2 (fibroblast growth factor 2) activity. FGF2 is implicated in not only angiogenesis but also fibrosis in several diseases including wet AMD. The dual action of RBM-007 (anti-angiogenic and anti-scarring) holds promise as an additive or alternative therapy to anti-VEGF treatments for wet AMD. Three studies are currently ongoing for wet AMD: 1. Active-controlled, double masked trial, TOFU study (NCT04200248); 2. Single-arm, open-label extension trial, RAMEN (NCT04640272); and 3. Investigator sponsored trial with treatment naïve wet AMD patients, the TEMPURA study (NCT04895293). The TOFU and RAMEN studies are active but closed to recruitment.

About RAMEN study
A Multi-Center, Open Label, TOFU Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects with Wet Age-related Macular Degeneration (RAMEN study) is a multi-center, open label, extension study assessing the efficacy and safety of additional intravitreal injections of RBM-007 in subjects with wet AMD.
See ClinicalTrials.gov for more information.
https://clinicaltrials.gov/ct2/show/NCT04640272

About wet Age-related Macular Degeneration
Wet (exudative) age-related macular degeneration, is the leading cause of blindness in the United States and Europe. It is caused by the formation of abnormal and leaky new blood vessels under the retina, termed choroidal neovascularization. The leakage of fluid from the vessels causes retinal

thickening and retinal degeneration including fibrotic scar formation, and leads to severe and rapid loss of vision.

ABOUT RIBOMIC

RIBOMIC is a clinical stage bio-pharmaceutical company specializing in the discovery and development of aptamer therapeutics, which is one type of nucleic acid medicine, a field with much potential for the development of next-generation drugs. The RiboART system, the company's core drug discovery platform, can be used for the discovery of many types of aptamer drugs. RIBOMIC is dedicated to the discovery and development of drugs that target the broad field of unmet medical needs, which encompasses eye disorders, pain and many other diseases.
See RIBOMIC website for more information.
https://www.ribomic.com/eng/

Forward-Looking Statements

This announcement contains forward-looking statements relating to current plans, estimates, strategies, belief and the future performance of Company. These statements are based on Company's current expectations in light of the information and assumptions currently available so that Company does not promise the realization and these expectations may differ materially from those discussed in the forward-looking statements. These factors include, but not limited to, i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, ii) currency exchange rate fluctuations, iii) claims and concerns on the product safety and efficacy, iv) completion and discontinuation of clinical trials, v) infringement of Company's intellectual property rights by third parties.
Information on pharmaceutical products (including products currently in development), which is included in this press release is not intended to constitute an advertisement or medical advice.

Contacts for inquiries or additional information:
RIBOMIC Inc.
Administration Division
ir.inquiry@ribomic.com